odmj
OncoDaily Medical Journal
ODMJ
3067-6444
OncoDaily Medical Journal
US
250
10.69690/ODMJ-001-1124-250
Original Research
The Experience of Hematologic Oncology in Armenia
Movsisyan
Alisa
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
alisamovsisyanmd@gmail.com
Hambardzumyan
Liana
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Ghahramanyan
Nerses
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Martirosyan
Nare
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Badikyan
Maria
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Immune Oncology Research Institute, Yerevan, Armenia
Grigoryan
Hayk
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Ter-Grigoryan
Anahit
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Saghumyan
Gevorg
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Evoyan
Levon
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Harutyunyan
Lusine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Farmazyan
Armine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Sevoyan
Anna
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Meliksetyan
Karen
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Saaryan
Miranush
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
https://orcid.org/0000-0002-9074-7831
Hakobyan
Yervand
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Melik-Andreasyan
Marine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia.
Oseyan
Hasmik
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Chakhoyan
Amalya
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Darbinyan
Avetis
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Movsisyan
Meri
Scientific Center of Traumatology and Orthopedics, Yerevan, Armenia
Hakobyan
Lusine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia.
Krmoyan
Lusine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia.
Saghatelyan
Tatul
National Center of Oncology, Yerevan, Armenia
Sargsyan
Anush
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
https://orcid.org/0000-0002-9331-1435
Sahakyan
Lusine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Sargsyan
Nelly
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia.
Khachatryan
Heghine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia.
Petrosyan
Lilit
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Bardakhchyan
Samvel
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Immune Oncology Research Institute, Yerevan, Armenia.
Bedirian
Karen
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Immune Oncology Research Institute, Yerevan, Armenia
Ghazaryan
Narine
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
Sargsyan
Lilit
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia.
Manukyan
Narek
Scientific Center of Traumatology and Orthopedics, Yerevan, Armenia
Muradyan
Armen
Yerevan State Medical University, Yerevan, Armenia
https://orcid.org/0000-0002-2740-9215
Tamamyan
Gevorg
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Yerevan State Medical University, Yerevan, Armenia. Immune Oncology Research Institute, Yerevan, Armenia
Danielyan
Samvel
Yeolyan Hematology and Oncology Center, Yerevan, Armenia
https://orcid.org/0000-0002-6949-506X
Voskanyan
Astghik
Yeolyan Hematology and Oncology Center, Yerevan, Armenia. Immune Oncology Research Institute, Yerevan, Armenia.
18
11
2024
ODMJ-001-1124-250
Copyright (c) 2024 OncoDaily Medical Journal
2024
OncoDaily Medical Journal
production-ready-file-url
[
World Bank. World Bank Open Data: Data for Armenia, Upper middle income [Internet]. 2023 [cited 2023 Jul 29]; [dataset]. Available from: https://data.worldbank.org
]
[
Worldometer. Armenia population [Internet]. 2023 [cited 2023 Jul 29]; [screen]. Available from: https://www.worldometers.info/world-population/armenia-population/
]
[
Government of the Republic of Armenia. About Armenia – Demographics [Internet]. [cited 2023 Jul 29]; Available from: https://www.gov.am/en/demographics/
]
[
Tsaturyan S, Scarpetti G. Health systems in action: Armenia. Copenhagen: WHO Regional Office for Europe; 2022.
]
[
Richardson E. Armenia: health system review. Health Syst Transit. 2013;15(4):1-99.
]
[
World Bank. Out-of-pocket expenditure (% of current health expenditure) – Armenia [Internet]. 2023 [cited 2023 Aug 1]; Available from: https://data.worldbank.org/indicator/SH.XPD.OOPC.CH.ZS?locations=AM
]
[
Global CPS Business and Legal Consulting. Health care system [Internet]. In: Invest in Armenia. [cited 2023 Aug 1]. Available from: http://investinarmenia.am/en/health-care-system
]
[
Petrosyan V, Martirosyan H. Armenia. In: Voluntary health insurance in Europe: country experience [Internet]. European Observatory on Health Systems and Policies; 2016 [cited 2023 Jul 31]. Available from: https://iris.who.int/handle/10665/330359
]
[
Hematology Center After Prof. R. Yeolyan [Internet]. [cited 2023 Sep 2]. Available from: https://blood.am/eng
]
[
Saif A, Kazmi SFA, Naseem R, Shah H, Butt MO. Acute myeloid leukemia: is that all there is? Cureus. 2018;10(8):e3198.
]
[
Chennamadhavuni A, Iyengar V, Mukkamalla SKR, Shimanovsky A. Leukemia. 2023 Jan 17. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
]
[
Khondkaryan L, Andreasyan D, Hakobyan Y, et al. Incidence and Risk Factors of Acute Leukemias in Armenia: A Population-Based Study. Asian Pac J Cancer Prev. 2022 Nov 1;23(11):3869-3875.
]
[
National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program: Acute Myeloid Leukemia – Cancer Stat Facts [Internet]. [cited 2023 Sep 5]. Available from: https://seer.cancer.gov/statfacts/html/amyl.html
]
[
National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program: Acute Lymphocytic Leukemia – Cancer Stat Facts [Internet]. [cited 2023 Sep 7]. Available from: https://seer.cancer.gov/statfacts/html/alyl.html
]
[
Döhner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, et al. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood. 2022 Sep 22;140(12):1345–77.
]
[
Rowe JM. The “7+3” regimen in acute myeloid leukemia. Haematologica. 2022 Jan 1;107(1):3.
]
[
Oxford Haematology NSSG. Cytarabine (Ara-C) high dose [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloid/protocols/ML-4-cytarabine-ara-c-3g-m2.pdf
]
[
Dutton D. Venetoclax and Cytarabine (low dose) acute myeloid leukaemia [Internet]. 2023;(1). Available from: https://www.clatterbridgecc.nhs.uk/application/files/3416/8198/0974/Venetoclax_and_Cytarabine_Low_Dose_Acute_Myeloid_Leukaemia_v1.0.pdf
]
[
Oxford Haematology NSSG. Azacitidine and venetoclax [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloid/protocols/ML-84-azacitidine-and-venetoclax-covid-19.pdf
]
[
Acute myeloid leukemia [Internet]. 2007 Sep 24 [cited 2023 Sep 4]. Available from: https://hemonc.medicine.ufl.edu/files/2013/07/AML1.pdf
]
[
Lo-Coco F, Avvisati G, Vignetti M, et al. Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013 Jul 11;369(2):111–21.
]
[
Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). Blood. 2012 Aug 23;120(8):1570–80.
]
[
Hoelzer D, Gökbuget N. Multicentric therapy optimization study of acute lymphatic leukemia in adults and adolescents from 18 years (GMALL 07/2003): therapy optimization by evaluating minimal residual disease – short protocol [in German]. 2003 Jul 30.
]
[
Gökbuget N. Consensus recommendation for the treatment of acute lymphoblastic leukemia (ALL) and lymphoblastic lymphoma (LBL) in adults/adolescents (18–55 years). Version 3 [in German]. 2017 Oct 16.
]
[
Volkova MA. Clinical oncohematology [in Russian]. Moscow: Medicine; 2001.
]
[
Aster JC, Stone RM. Clinical manifestations, diagnosis, and classification of myelodysplastic syndromes (MDS). In: Post TW, editor. UpToDate [Internet]. Waltham (MA): UpToDate; 2023 [cited 2023 Aug 20]. Available from: https://www.uptodate.com/contents/clinical-manifestations-diagnosis-and-classification-of-myelodysplastic-syndromes-mds
]
[
Wang F, Ni J, Wu L, Wang Y, He B, Yu D. Gender disparity in the survival of patients with primary myelodysplastic syndrome. J Cancer. 2019 Jan 30;10(5):1325–32.
]
[
Jiang Y, Eveillard JR, Couturier MA, et al. Asian Population Is More Prone to Develop High-Risk Myelodysplastic Syndrome, Concordantly with Their Propensity to Exhibit High-Risk Cytogenetic Aberrations. Cancers. 2021 Jan 27;13(3):481.
]
[
Sekeres MA, Taylor J. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review. JAMA. 2022 Sep 6;328(9):872.
]
[
Harutyunyan L, Voskanyan A, Meliksetyan K, Sahakyan L, Chakmanyan A, Sargsyan G, et al. CML-307: Assessment of 5-Year OS and Treatment Options in Newly Diagnosed Ph + CML Patients in the Republic of Armenia. Clin Lymphoma Myeloma Leuk. 2021 Sep 1;21:S333.
]
[
Harutyunyan L, Meliksetyan K, Ivanyan A, Hakobyan Y. CML-218: Primary Diagnosed CML Patient 5-Year Treatment Outcomes and Disease Incidence in an Armenian Population. Clin Lymphoma Myeloma Leuk. 2020 Sep 1;20:S237–8.
]
[
Gerds AT, Gotlib J, Ali H, et al. Myeloproliferative Neoplasms, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2022 Sep;20(9):1033–62.
]
[
Sahakyan L, Ter-Grigoryan A, Badikyan M, et al. Incidence in PH-negative myeloproliferative neoplasms in Armenia from 2005 to 2019. Hematol Transfus Cell Ther. 2020 Oct 1;42:19–20.
]
[
Verstovsek S, Yu J, Scherber RM, et al. Changes in the incidence and overall survival of patients with myeloproliferative neoplasms between 2002 and 2016 in the United States. Leuk Lymphoma. 2022 Feb 23;63(3):694–702.
]
[
Voskanyan A, Ter-Grigoryan A, Meliksetyan K, et al. MPN-270 Challenges of the Management of Primary Myelofibrosis in Armenia. Clin Lymphoma Myeloma Leuk. 2022 Oct;22 Suppl 2:S332.
]
[
Grigoryan H, Badikyan M, Hambardzumyan L, et al. MPN-200: Essential Thrombocythemia in Armenia: A Nationwide Study. Clin Lymphoma Myeloma Leuk. 2020 Sep 1;20:S333–4.
]
[
SEER Hematopoietic and Lymphoid Neoplasm Database. Essential thrombocythemia [Internet]. SEER; [cited 2023 Sep 8]. Available from: https://seer.cancer.gov/seertools/hemelymph/51f6cf58e3e27c3994bd53ff/
]
[
Barbui T, Thiele J, Passamonti F, et al. Survival and Disease Progression in Essential Thrombocythemia Are Significantly Influenced by Accurate Morphologic Diagnosis: An International Study. J Clin Oncol. 2011 Aug 10;29(23):3179–84.
]
[
Mukkamalla SKR, Taneja A, Malipeddi D, Master SR. Chronic lymphocytic leukemia. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Sep 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK470433/
]
[
National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program: Chronic Lymphocytic Leukemia – Cancer Stat Facts [Internet]. [cited 2024 Jan 9]. Available from: https://seer.cancer.gov/statfacts/html/clyl.html
]
[
Macrotrends. Armenia life expectancy 1950–2023 [Internet]. [cited 2023 Sep 19]. Available from: https://www.macrotrends.net/countries/ARM/armenia/life-expectancy
]
[
Macrotrends. U.S. life expectancy 1950–2023 [Internet]. [cited 2023 Sep 19]. Available from: https://www.macrotrends.net/countries/USA/united-states/life-expectancy
]
[
Gribben JG. How I treat CLL up front. Blood. 2010 Jan 14;115(2):187–97.
]
[
Oxford Haematology NSSG. Bendamustine + rituximab (BR) for CLL [Internet]. [cited 2023 Sep 8]. Available from: https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-44-bendamustine-70-r-cll.pdf
]
[
Oxford Haematology NSSG. Fludarabine cyclophosphamide rituximab (FCR) intravenous [Internet]. [cited 2023 Sep 8]. Available from: https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-29-flu-cy-r-iv.pdf
]
[
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
]
[
Kazandjian D. Multiple myeloma epidemiology and survival: A unique malignancy. Semin Oncol. 2016 Dec;43(6):676–81.
]
[
Oganesyan A, Ghahramanyan N, Mekinian A, Bejanyan N, Kazandjian D, Hakobyan Y. Managing multiple myeloma in a resource-limited region: Diagnosis and treatment in Armenia. Semin Oncol. 2021;48(4–6):269–78.
]
[
Ghazaryan N, Danelyan S, Bardakhchyan S, Saharyan A, Sahakyan L. Multiple myeloma in Armenia during the period 2006–2018: facts and discussion. BMC Cancer. 2021 Aug 21;21(1):941.
]
[
Mateos MV, Ailawadhi S, Costa LJ, et al. Global disparities in patients with multiple myeloma: a rapid evidence assessment. Blood Cancer J. 2023 Jul 18;13(1):1–9.
]
[
National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program: Myeloma – Cancer Stat Facts [Internet]. [cited 2023 Sep 7]. Available from: https://seer.cancer.gov/statfacts/html/mulmy.html
]
[
SWAG Cancer Alliance. Bortezomib, cyclophosphamide and dexamethasone (VCD) [Internet]. [cited 2023 Sep 4]. Available from: https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2020/10/VCD.pdf
]
[
Oxford Haematology NSSG. Bortezomib lenalidomide and dexamethasone (VRD) [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloma/pdf-protocols/MM-6-bortezomib-len-dex.pdf
]
[
SWAG Cancer Alliance. Lenalidomide and dexamethasone (Rd) – second line onwards [Internet]. [cited 2023 Sep 4]. Available from: https://www.swagcanceralliance.nhs.uk/wp-content/uploads/2020/10/Lenalidomide-and-dex-subsequent.pdf
]
[
Oxford Haematology NSSG. Oral cyclophosphamide with or without prednisolone [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloma/pdf-protocols/MM-13-cyclophosphamide.pdf
]
[
University Hospital Southampton NHS Foundation Trust. PAD (IV) – bortezomib (IV), dexamethasone, doxorubicin [Internet]. [cited 2023 Sep 4]. Available from: https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaPAD-BortezomibIVDexamethasoneDoxorubicinVer1.pdf
]
[
Oxford Haematology NSSG. Bortezomib thalidomide and dexamethasone (VTD21), 21-day cycle [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloma/pdf-protocols/MM-7-bortezomib-thal-dex-21d.pdf
]
[
Kyle RA, Jacobus S, Friedenberg WR, Slabber CF, Rajkumar SV, Greipp PR. The treatment of multiple myeloma using vincristine, carmustine, melphalan, cyclophosphamide, and prednisone (VBMCP) alternating with high-dose cyclophosphamide and α2β interferon versus VBMCP. Cancer. 2009;115(10):2155–64.
]
[
Oxford Haematology NSSG. Oral melphalan ± prednisolone [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloma/pdf-protocols/MM-20-melphalan-pred.pdf
]
[
Oxford Haematology NSSG. Thalidomide with or without dexamethasone [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloma/pdf-protocols/MM-23-thalidomide-plus-minus-dex.pdf
]
[
Oxford Haematology NSSG. Lenalidomide, cyclophosphamide and weekly dexamethasone [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/myeloma/pdf-protocols/MM-17-lena-cyclop-dex.pdf
]
[
Sahakyan L, Harutyunyan L, Voskanyan A, et al. ABCL-258 Incidence Patterns of Non-Hodgkin Lymphoma in the Republic of Armenia. Clin Lymphoma Myeloma Leuk. 2022 Oct 1;22:S366.
]
[
Padala SA, Kallam A. Diffuse large B-cell lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Sep 8]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK557833/
]
[
University Hospital Southampton NHS Foundation Trust. RCVP – cyclophosphamide, prednisolone, rituximab, vincristine (Ver. 1.2) [Internet]. [cited 2023 Sep 4]. Available from: https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf
]
[
University Hospital Southampton NHS Foundation Trust. RCVP – cyclophosphamide, prednisolone, rituximab, vincristine (Ver. 1.2) [Internet]. [cited 2023 Sep 4]. Available from: https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/RCVP-Cyclophosphamide-Prednisolone-Rituximab-Vincristine-Ver-1.2.pdf
]
[
University Hospital Southampton NHS Foundation Trust. CVP – cyclophosphamide, prednisolone, vincristine (Ver. 1.2) [Internet]. [cited 2023 Sep 4]. Available from: https://www.uhs.nhs.uk/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Lymphoma/CVP-Cyclophosphamide-Prednisolone-Vincristine-Ver-1.2.pdf
]
[
Bhurani D, Nair R, Rajappa S, et al. Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India. Front Oncol. 2021;11:799948.
]
[
Arakelyan J, Movsisyan A, Sargsyan L, et al. Incidence patterns and review of Hodgkin lymphoma in the Republic of Armenia. Ecancermedicalscience. 2021 Nov 18;15:1319.
]
[
National Institutes of Health. Surveillance, Epidemiology, and End Results (SEER) Program: Hodgkin lymphoma – Cancer Stat Facts [Internet]. [cited 2023 Sep 7]. Available from: https://seer.cancer.gov/statfacts/html/hodg.html
]
[
Kaseb H, Babiker HM. Hodgkin lymphoma. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2023 [cited 2023 Aug 4]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK499969/
]
[
Oxford Haematology NSSG. ABVD [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-8%20-%20abvd.pdf
]
[
Oxford Haematology NSSG. BEACOPP-14 / BEACOPP-escalated [Internet]. [cited 2023 Sep 4]. Available from: https://nssg.oxford-haematology.org.uk/lymphoma/documents/lymphoma-chemo-protocols/L-18-beacopp-14-or-beacopp-escalated.pdf
]
[
Immune Oncology Research Institute. Assessment of the safety and efficacy of balstilimab for the treatment of relapsed/refractory lymphomas (IMMONC0001) [Internet]. clinicaltrials.gov; 2023 May [cited 2023 Sep 1]. Report No.: NCT05891821. Available from: https://clinicaltrials.gov/study/NCT05891821
]
[
Barton MB, Jacob S, Shafiq J, et al. Estimating the demand for radiotherapy from the evidence: A review of changes from 2003 to 2012. Radiother Oncol. 2014 Jul 1;112(1):140–4.
]
[
Immune Oncology Research Institute. Blastic plasmacytoid dendritic cell neoplasm (BPDCN) international registry [Internet]. clinicaltrials.gov; 2023 Aug [cited 2023 Sep 1]. Report No.: NCT05430971. Available from: https://clinicaltrials.gov/study/NCT05430971
]
[
Astex Pharmaceuticals, Inc. Study to evaluate the pharmacokinetics and safety of oral decitabine and cedazuridine in cancer patients with renal impairment [Internet]. clinicaltrials.gov; 2021 Jul 9 [cited 2024 Aug 31]. Report No.: NCT04953897. Available from: https://clinicaltrials.gov/study/NCT04953897
]